Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke

Maryam Salaudeen, Stuart Allan, Emmanuel Pinteaux

Research output: Contribution to journalReview articlepeer-review


Promising preclinical stroke research has not yielded meaningful and significant success in clinical trials. This lack of success has prompted the need for refinement of preclinical studies with the intent to optimize the chances of clinical success. Regenerative medicine, especially using mesenchymal stem/stromal cells (MSCs), has gained popularity in the last decade for treating many disorders, including central nervous system (CNS), such as stroke. In addition to less stringent ethical constraints, the ample availability of MSCs also makes them an attractive alternative to totipotent and other pluripotent stem cells. The ability of MSCs to differentiate into neurons and other brain parenchymal and immune cells makes them a promising therapy for stroke. However, these cells also have some drawbacks that, if not addressed, will render MSCs unfit for treating ischaemic stroke. In this review, we highlighted the molecular and cellular changes that occur following an ischaemic stroke (IS) incidence and discussed the physiological properties of MSCs suitable for tackling these changes. We also went further to discuss the major drawbacks of utilizing MSCs in IS and how adequate priming using both hypoxia and interleukin-1 can optimize the beneficial properties of MSCs while eliminating these drawbacks.
Original languageEnglish
Pages (from-to)154-166
Number of pages13
JournalHuman Cell
Issue number1
Early online date23 Nov 2023
Publication statusPublished - 1 Jan 2024


  • Hypoxia
  • Ischemia
  • Mesenchymal stem/stromal cell
  • Priming
  • Stroke


Dive into the research topics of 'Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke'. Together they form a unique fingerprint.

Cite this